Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study

Christophe Massard; Heidi Penttinen; Egils Vjaters; Petri Bono; Vilnis Lietuvietis; Teuvo Tammela; Annamari Vuorela; Pirjo Nykänen; Pasi Pohjanjousi; Amir Snapir; Karim Fizazi

doi:10.1016/j.eururo.2015.09.046

Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study

Christophe Massard, Heidi Penttinen, Egils Vjaters, Petri Bono, Vilnis Lietuvietis, Teuvo Tammela, Annamari Vuorela, Pirjo Nykänen, Pasi Pohjanjousi, Amir Snapir, Karim Fizazi

Research output: Contribution to journal › Article › Scientific › peer-review

61 Citations (Scopus)

Original language	English
Pages (from-to)	834-40
Journal	European Urology
Volume	69
Issue number	5
Early online date	2015
DOIs	https://doi.org/10.1016/j.eururo.2015.09.046
Publication status	Published - 2016
Publication type	A1 Journal article-refereed

Keywords

ODM-201
androgen receptor inhibitor
castration-resistant prostate cancer

Publication forum classification

Publication forum level 3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2015.09.046

Cite this

Massard, C., Penttinen, H., Vjaters, E., Bono, P., Lietuvietis, V., Tammela, T., Vuorela, A., Nykänen, P., Pohjanjousi, P., Snapir, A., & Fizazi, K. (2016). Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study. European Urology, 69(5), 834-40. https://doi.org/10.1016/j.eururo.2015.09.046

@article{ae6462a6921c4379b94ad84e02e1b19f,

title = "Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study",

keywords = "ODM-201, androgen receptor inhibitor, castration-resistant prostate cancer, ODM-201, androgen receptor inhibitor, castration-resistant prostate cancer",

author = "Christophe Massard and Heidi Penttinen and Egils Vjaters and Petri Bono and Vilnis Lietuvietis and Teuvo Tammela and Annamari Vuorela and Pirjo Nyk{\"a}nen and Pasi Pohjanjousi and Amir Snapir and Karim Fizazi",

year = "2016",

doi = "10.1016/j.eururo.2015.09.046",

language = "English",

volume = "69",

pages = "834--40",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "5",

}

Massard, C, Penttinen, H, Vjaters, E, Bono, P, Lietuvietis, V, Tammela, T, Vuorela, A, Nykänen, P, Pohjanjousi, P, Snapir, A & Fizazi, K 2016, 'Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study', European Urology, vol. 69, no. 5, pp. 834-40. https://doi.org/10.1016/j.eururo.2015.09.046

Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study. / Massard, Christophe; Penttinen, Heidi; Vjaters, Egils et al.
In: European Urology, Vol. 69, No. 5, 2016, p. 834-40.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer : an open-label phase 1 study

AU - Massard, Christophe

AU - Penttinen, Heidi

AU - Vjaters, Egils

AU - Bono, Petri

AU - Lietuvietis, Vilnis

AU - Tammela, Teuvo

AU - Vuorela, Annamari

AU - Nykänen, Pirjo

AU - Pohjanjousi, Pasi

AU - Snapir, Amir

AU - Fizazi, Karim

PY - 2016

Y1 - 2016

KW - ODM-201

KW - androgen receptor inhibitor

KW - castration-resistant prostate cancer

KW - ODM-201

KW - androgen receptor inhibitor

KW - castration-resistant prostate cancer

U2 - 10.1016/j.eururo.2015.09.046

DO - 10.1016/j.eururo.2015.09.046

M3 - Article

SN - 0302-2838

VL - 69

SP - 834

EP - 840

JO - European Urology

JF - European Urology

IS - 5

ER -